In conclusion, our results strongly suggest that the selective VEGFR‐1 inhibition by D16F7 mAb might potentiate the effects of vemurafenib‐based therapies for melanoma treatment and counteract resistance development to this BRAFi. This evidence concerns the gene FLT1 and melanoma.